CompletedPhase 4NCT00361140

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
Teresa Field, PhD, MD, PA-C
H. Lee Moffitt Cancer Center and Research Institute
Intervention
Busulfan(drug)
Enrollment
72 enrolled
Eligibility
16-65 years · All sexes
Timeline
20052012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00361140 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials